Pinto Lorenzo Maria, Chiricozzi Andrea, Calabrese Laura, Mannino Maria, Peris Ketty
UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Pharmaceutics. 2022 Dec 10;14(12):2767. doi: 10.3390/pharmaceutics14122767.
Topical agents that are currently available for the treatment of atopic dermatitis may represent a valid approach in the management of mild or mild-moderate cases, whereas they are often supplemented with systemic therapies for handling more complex or unresponsive cases. The most used compounds include topical corticosteroids and calcineurin inhibitors, although their use might be burdened by side effects, poor response, and low patient compliance. Consequently, new innovative drugs with higher efficacy and safety both in the short and long term need to be integrated into clinical practice. A deeper understanding of the complex pathogenesis of the disease has led to identifying new therapeutic targets and to the development of innovative therapeutics. This narrative review aims to collect data on selected promising topical drugs that are in an advanced stage of development.
目前可用于治疗特应性皮炎的局部用药可能是轻度或轻度至中度病例管理中的一种有效方法，而对于更复杂或反应不佳的病例，通常会辅以全身治疗。最常用的化合物包括外用皮质类固醇和钙调神经磷酸酶抑制剂，尽管它们的使用可能会受到副作用、反应不佳和患者依从性低的影响。因此，需要将在短期和长期内具有更高疗效和安全性的新型创新药物纳入临床实践。对该疾病复杂发病机制的更深入理解已促使人们确定新的治疗靶点并开发创新疗法。本叙述性综述旨在收集有关处于研发后期的选定有前景的局部用药的数据。
